Emtricitabine; Tenofovir Alafenamide Fumarate Patent Expiration
Emtricitabine; Tenofovir Alafenamide Fumarate is Used for managing and treating HIV infection. It was first introduced by Gilead Sciences Inc
Emtricitabine; Tenofovir Alafenamide Fumarate Patents
Given below is the list of patents protecting Emtricitabine; Tenofovir Alafenamide Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Descovy | US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep 29, 2015
(Expired) | Gilead Sciences Inc |
| Descovy |
US5814639 (Pediatric) | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar 29, 2016
(Expired) | Gilead Sciences Inc |
| Descovy | US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul 02, 2017
(Expired) | Gilead Sciences Inc |
| Descovy |
US5914331 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan 02, 2018
(Expired) | Gilead Sciences Inc |
| Descovy | US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov 04, 2020
(Expired) | Gilead Sciences Inc |
| Descovy |
US6642245 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May 04, 2021
(Expired) | Gilead Sciences Inc |
| Descovy | US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar 09, 2021
(Expired) | Gilead Sciences Inc |
| Descovy |
US6703396 (Pediatric) | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep 09, 2021
(Expired) | Gilead Sciences Inc |
| Descovy | US7390791 | Prodrugs of phosphonate nucleotide analogues | Apr 17, 2025 | Gilead Sciences Inc |
| Descovy |
US7390791 (Pediatric) | Prodrugs of phosphonate nucleotide analogues | Oct 17, 2025 | Gilead Sciences Inc |
| Descovy | US7803788 | Prodrugs of phosphonate nucoleotide analogues |
Feb 02, 2022
(Expired) | Gilead Sciences Inc |
| Descovy | US8754065 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Descovy |
US8754065 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
| Descovy | US9296769 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Descovy |
US9296769 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Emtricitabine; Tenofovir Alafenamide Fumarate Generics
Several generic applications have been filed for Emtricitabine; Tenofovir Alafenamide Fumarate.
Given below is the list of companies who have filed for Emtricitabine; Tenofovir Alafenamide Fumarate generic.
1. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Emtricitabine; Tenofovir Alafenamide Fumarate. All of these versions come by the name EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 120MG; EQ 15MG BASE | tablet | Prescription | ORAL | AB | May 17, 2024 |
| 200MG; EQ 25MG BASE | tablet | Prescription | ORAL | AB | May 17, 2024 |